Technology/ Title

Anti-Globo H Bispecific Antibody

Technology Type

□Biotechnology

□Device/Diagnostics

Pharmaceutical

□Others:_____________-

Contact Person

 

Name: Joseph Liu

Title: Project Manager

Telephone(work):

+886-02-7700-3800 ext. 5237

Mobile:

Email: joseph.liu@dcb.org.tw

Link

http://

 

 

Technology Description

 

Summary of Invention:

Globo H is one of the surface markers in various cancer cells, including breast cancer, ovarian cancer, pancreatic cancer, prostate cancer , thyroid cancer, and liver cancer. The anti-Globo H x anti-CD3 bispecific antibody targets Globo H expressing cancer cells and engages the T cells for cancer therapy.

 

Advantages when compared to the existing technologies:

  • In contrast to the anti-Her2 mAb (i.e. Trastuzumab) which targets 20% of breast cancer patients, the anti-Globo H x anti-CD3 BsAb will cover more than 60% of total breast cancer patients.
  • With the specificity to Globo H, the BsAb enhances the antibody-mediated tumor cell eradication by recruiting and activating T cell into the tumor microenvironment.

Intellectual Property

US, PCT, TW patents filed

Key Publications

 

 

Business Opportunity

T-cell engager-mediated cancer therapy

 

▌技術簡介(現況)
該雙特異性抗體對醣抗原Globo H表現之細胞具有專一性,可介導並活化T細胞,進而應用在癌症治療之上。

▌技術規格
非對稱性IgG構型之anti-Globo H/anti-CD3 雙特異性抗體

▌技術特色

  1. 有別於市售抗體Trastuzumab限用於具HER2高度表現之乳癌病患,僅佔乳癌病患之20%,本雙特異性抗體可適用於具 Globo H陽性之乳癌病患,嘉惠60%之乳癌病患。近年來文獻指出,Globo H在肺癌、卵巢癌、胰臟癌、攝護腺癌、甲狀腺癌與肝癌有顯著表現,可以作為外來發展藥物的標的。
  2. 利用該雙特異性抗體對醣抗原Globo H之專一性,促進T細胞在腫瘤微環境之聚集與活化,進一步介導細胞毒殺作用清除癌細胞。

▌應用範圍
適應症為具醣抗原Globo H陽性之腫瘤,例如乳癌、肺癌、卵巢癌、胰臟癌、攝護腺癌、甲狀腺癌與肝癌。

▌接受技術者具備基礎建議(設備)
細胞及分子生物學實驗設施、抗體表現與純化系統。

▌接受技術者具備基礎建議(專業)
抗體臨床前開發技能。

▌技術分類
抗體藥物開發

▌專利狀態


聯絡人: 鍾牧樺
TEL:  (02)7700-3800 #5235
E-mail:  tony.chung@dcb.org.tw

最後更新日期:2018.04.30